The increase of the aging population presents immense opportunities for bio-pharmaceutical companies to develop candidates to treat global ailments. Dozens of biotech stocks continue to generate significant gains for investors and as the average lifespan continues to increase, the number of drugs being developed to hit the market should follow.
The potential for share prices to skyrocket instantaneously on favorable trial news or possible FDA approval is what continues to lure investors into the space.
The NASDAQ Biotechnology Index (NBI) and the iShares NASDAQ Biotech EFT (IBB) are both up about 12 percent over the last trailing year, while the SPDR S&P Biotech ETF (XBI) is showing gains over 20 percent. As the sector continues to heat up, here are 3 bio-pharmaceutical companies that could have potential in their pipelines.